Twelve mongrel dogs were randomly allocated into two groups using matched paired-design. Catheters were inserted into the hepatic artery, hepatic vein and the femoral vein, respectively. In the first group, gelfoam supplemented with mitomycin C (MMC) was injected into the hepatic artery, whereas the second group received a hepatic arterial injection of MMC solution alone. Simultaneous blood sampling from the hepatic and femoral veins at regular intervals was performed. MMC concentrations in plasma was determined using high performance liquid chromatography (HPLC) and the pharmacokinetics of MMC were determined.
INTRODUCTION
Mitomycin C (MMC) is an antitumor drug with supposed broad spectrum of antitumor activity, first isolated from Streptomyces caespitosus by Wakaki et al. in 1958. The previously used low-dose regimen caused severe myelosuppression, resulting in only limited use of the drug in the last 20 years. The myelosuppressive adverse effect diminished to a great extent by using a high-dose intermittent schedule2. Following advances in understanding of the blood supply of hepatic tumors it was found that liver cancer derives its blood supply almost exclusively from the hepatic artery3. This fact focused attention on local treatment The similar pharmacokinetics of MMC following both therapies might be explained by the following mechanisms. As gelfoam particles only occupied a small part of the 20 ml of MMC solution, a large proportion of the drug could be expected to be in a free state. Also the arterial pressure distal to the embolized arteries reduces, thereby increasing the pressure gradient to the systemic circulation after hepatic arterial embolization, inducing opening of pre-existing collaterals and arterioportal shunts34-37. Non-encapsulated MMC might also be metabolized by liver enzymes.
In conclusion, our results show that the pharmacokinetic behavior of MMC was similar both following hepatic arterial chemoembolization using MMC and gelfoam and hepatic arterial injection of MMC alone. This implies that mechanical embolization using gelfoam is not sufficient to prolong MMC clearance from liver tissue. Further studies on MMC with these embolic materials and using the method established in this paper are looked forward to.
